AGENDA

Uniform Formulary Beneficiary Advisory Panel
9 January 2013 @ 0900 AM

Naval Heritage Center Theater
701 Pennsylvania Ave. NW., Washington DC 20004

- Administrative Meeting (BAP members only @ 7:30 AM-9:00 AM)
- Sign-In
- Welcome and Opening Remarks
- Public Citizen Comments
- Therapeutic Class Reviews

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations of the following drug classes during the Nov 2012 meeting:

- **Drug Class Reviews:**
  - Non-Insulin Diabetes Drugs—Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)
  - Overactive Bladder Drugs (OAB)
  - Gastrointestinal-2 Oral Antibiotic Drugs (GI-2)
  - Hepatitis C Drugs

- **Designated Newly Approved Drugs:**
  - High Potency Narcotic Analgesics—Oxycodone immediate release (Oxecta)

- **Re-evaluation of Non-formulary Agents**—Status of escitalopram (Lexapro) and pantoprazole (Protonix) on the Uniform Formulary

- **Utilization Management Issues**
  - Prior Authorization Criteria
    - DrugPhosphodiesterase-5 (PDE-5) Inhibitors
    - Topical Testosterone Replacement Therapy (TRT)—Use in women
    - Injectable Gonadotropins
- Targeted Immunomodulatory Biologics—Adalimumab (Humira)
- Prostate Cancer Drugs—Enzalutamide (Xtandi) and Abiratone (Zytiga)

➢ Panel Discussions

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.